By Bhanvi Satija

LONDON (Reuters) -WeightWatchers’ CEO said on Wednesday it plans to sell Novo Nordisk’s much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.

The collaboration is a potential boost for WeightWatchers as it emerges from bankruptcy and highlights its commitment to sell branded obesity drugs, unlike rivals that push cheaper copies in a highly competitive market.

“We have been working with Novo Nordisk ahead of time to support the launch of oral weight-loss medication,” WeightWatchers CEO Tara Comonte said in an interview.

“A lot of people don’t want an injection. And the convenience of a pill is going to be huge,” she said.

Weight loss pills from Novo and rival Eli Lilly are under co

See Full Page